EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer (Q80100696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

non-small-cell lung carcinoma

28 December 2019

main subject

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Hideharu Kimura

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kazuo Kasahara

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kazuhiko Shibata

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Takashi Sone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Akihiro Yoshimoto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yukari Ichikawa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yuko Waseda

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kazuyoshi Watanabe

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hiroki Shiarasaki

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yoshihisa Ishiura

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Masayuki Mizuguchi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yasuto Nakatsumi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Tatsuhiko Kashii

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Masashi Kobayashi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hideo Kunitoh

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Tomohide Tamura

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kazuto Nishio

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Masaki Fujimura

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Shinji Nakao

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

260-267

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

Estimating the world cancer burden: Globocan 2000.

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

The ErbB/HER receptor protein-tyrosine kinases and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

The biology of epidermal growth factor receptor in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Gefitinib (Iressa) trials in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931577-X

7 January 2021

10.1016/S1556-0864(15)31577-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409866%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference